S&P 500

5.307,01

-0,27%

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

SESN

Sesen Bio (SESN)

Sesen Bio Inc

Von:

Regulatory News

Text Search:

Sortieren nach:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:SESN

1 2 3 4 5 6 7 8 9 10 Next >>

Datum	Zeit	Quelle	Überschrift	Symbol	Firma
10/08/2023	13h30	PR Newswire (US)	Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights	NASDAQ:SESN	Sesen Bio Inc
06/03/2023	18h41	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
06/03/2023	18h35	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:SESN	Sesen Bio Inc
03/03/2023	17h07	Edgar (US Regulatory)	Sec Staff Action/letter (sec Staff)	NASDAQ:SESN	Sesen Bio Inc
03/03/2023	17h06	Edgar (US Regulatory)	Sec Staff Action/letter (sec Staff)	NASDAQ:SESN	Sesen Bio Inc
02/03/2023	18h07	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:SESN	Sesen Bio Inc
02/03/2023	17h32	Business Wire	Sesen Bio Stockholders Approve Merger with Carisma Therapeutics	NASDAQ:SESN	Sesen Bio Inc
28/02/2023	14h08	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
28/02/2023	14h03	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:SESN	Sesen Bio Inc
28/02/2023	14h02	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:SESN	Sesen Bio Inc
28/02/2023	14h00	Business Wire	Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results	NASDAQ:SESN	Sesen Bio Inc
27/02/2023	22h33	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
27/02/2023	14h02	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:SESN	Sesen Bio Inc
21/02/2023	15h05	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
21/02/2023	15h00	Business Wire	Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma	NASDAQ:SESN	Sesen Bio Inc
17/02/2023	14h18	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
17/02/2023	14h08	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
17/02/2023	14h04	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
17/02/2023	14h02	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
16/02/2023	23h06	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)	NASDAQ:SESN	Sesen Bio Inc
16/02/2023	22h46	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
16/02/2023	22h42	Business Wire	Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting	NASDAQ:SESN	Sesen Bio Inc
16/02/2023	14h02	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
16/02/2023	14h00	Business Wire	Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger	NASDAQ:SESN	Sesen Bio Inc
15/02/2023	22h55	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:SESN	Sesen Bio Inc
15/02/2023	14h02	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
15/02/2023	14h00	Business Wire	BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics	NASDAQ:SESN	Sesen Bio Inc
14/02/2023	22h40	Edgar (US Regulatory)	Registration Pursuant to Securities Act Rule 462(b) of up to an Additional 20% of Securities for an Offering That Was Registered on a Form S-4 (s-4mef)	NASDAQ:SESN	Sesen Bio Inc
14/02/2023	15h08	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
14/02/2023	14h00	Business Wire	Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger	NASDAQ:SESN	Sesen Bio Inc